Guillaume Jesel Promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development
Today, The Estée Lauder Companies (NYSE: EL) (“ELC”) announced that Guillaume Jesel has been promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development, effective immediately. Guillaume will report to Jane Hertzmark Hudis, Executive Group President and also to Tracey T. Travis, Executive Vice President and Chief Financial Officer in her role of overseeing the company’s mergers and acquisitions strategy, for Guillaume’s Luxury Business Development responsibilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005235/en/
Guillaume Jesel has been promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development (Photo: Business Wire)
In this new position, Guillaume will continue to oversee TOM FORD BEAUTY and also be responsible for the overall strategic direction, global development, management and growth of BALMAIN BEAUTY. Guillaume will work closely with the leadership of BALMAIN to translate its visionary creative into a winning luxury beauty brand globally. In addition to his newly expanded brand leadership responsibilities, Guillaume will continue to play a key role in prospective acquisitions and investment strategy for ELC’s luxury business development.
“Guillaume’s exceptional understanding of aspirational luxury and his strong brand strategy expertise have been instrumental to the success of TOM FORD BEAUTY,” said Ms. Hertzmark Hudis. “This makes him well-positioned to oversee our new luxury brand, BALMAIN BEAUTY.”
With regards to this appointment, Olivier Rousteing, Creative Director of BALMAIN said, “Guillaume is one of the most creative and passionate executives that I have seen in the industry today and I know he will help build BALMAIN BEAUTY into a global beauty brand for all.”
Guillaume’s elevation to President, Global Brands, recognizes his tremendous talent in building coveted brands and hero franchises. With TOM FORD BEAUTY for the past eight years, Guillaume spearheaded iconic innovation and strategically expanded the brand’s reach around the world, firmly establishing TOM FORD BEAUTY as a powerhouse in luxury beauty. Most recently as Global Brand President since July 2016, Guillaume led the brand to achieve strong net sales growth on a compound annual basis and significantly improve ranking in each of global prestige fragrance and makeup. A Global General Manager for TOM FORD BEAUTY, who will report to Guillaume, will be announced at a later date.
Prior to leading TOM FORD BEAUTY, Guillaume spent a decade with M·A·C Cosmetics, where he contributed to propelling the brand to the #1 ranking in global prestige makeup. Guillaume also served in a number of other senior roles since joining ELC in 2000, including Vice President, Global Makeup Marketing, Estée Lauder, and Senior Vice President, Global and North America Marketing, M·A·C Cosmetics. At Estée Lauder, he led a collaboration with Tom Ford to create limited-edition collections that served as a precursor to the standalone TOM FORD BEAUTY.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies (“ELC”) is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, Aerin Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, Kilian Paris, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
About TOM FORD BEAUTY
TOM FORD BEAUTY is a complete collection of iconic fragrances, sensuous color, and high-performance skin treatments that empower anyone to amplify their individuality, enhance their beauty, and achieve bold modern glamour.
About BALMAIN
For more than ten years, BALMAIN’s Creative Director, Olivier Rousteing, has been inventively building upon Pierre Balmain’s extraordinary legacy, while always remaining true to his own determination to design clothes that reflect the way his inclusive, powerful, and global BALMAIN customer wishes to live today. The result is a unique and instantly recognizable BALMAIN silhouette, style and attitude that highlights the singular craftsmanship of the house’s celebrated ateliers, while consistently referencing a rich Parisian heritage. For more information, please visit balmain.com.
ELC-L
ELC-C
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005235/en/
Contact information
News
Investor Relations:
Rainey Mancini
rmancini@estee.com
Media Relations:
Jill Marvin
jimarvin@estee.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom